conditioning intensity and genomics: relapse after allogeneic transplant in mds
Published 4 years ago • 142 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
6:20
maintenance therapy after allogeneic hsct in mds
-
6:59
reduced-intensity conditioning regimens in all patients undergoing allo-hsct
-
2:34
impact of conditioning intensity of allo-sct for aml with molecular residual disease
-
1:26
ric allogeneic hct for high-risk mds
-
1:03
reduced intensity vs myeloablative conditioning regimens in patients with aml and mds
-
4:03
the conditioning regimen
-
3:08
george's story: what advice do you have for other patients on their journey with mds?
-
1:49
advances in the science and treatment of mpns
-
0:53
how to improve transplant outcomes in mds?
-
0:41
the role of transplantation in mds
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
8:34
hct in mds: cell source and conditioning type
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies
-
1:27
the impact of inflammation & the microenvironment in the development and progression of mds
-
4:03
flamsa-reduced intensity vs myeloablative conditioning for r/r aml with disease at transplantation
-
0:55
total body irradiation vs. chemotherapy-based myeloablative conditioning for asct
-
2:35
methods of optimizing transplantation in mds
-
3:16
allogeneic transplant for older aml patients - who, when and how
-
3:02
optimizing transfusion support in mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:15
optimizing transplantation for mds
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml